GLP-1 Lawsuits Surge Over Rare 'Eye Stroke' Claims

Key points

• Hundreds of lawsuits have been filed against Novo Nordisk and Eli Lilly, alleging that GLP-1 drugs cause nonarteritic anterior ischemic optic neuropathy (NAION).
• NAION is a rare condition causing sudden, often permanent vision loss, with no known treatment.
• The condition is not listed on U.S. drug labels, though some countries have added warnings.
• Manufacturers deny causation, citing mixed research and low absolute risk.
• The FDA is reviewing the evidence but has not issued a safety warning.

Background

This story follows earlier reports from our archive (2026-09-22 to 2026-09-24) detailing the surge in lawsuits against GLP-1 makers over NAION. Previous coverage noted that while manufacturers deny causation, some countries have updated drug labels, and the FDA is investigating the potential connection.

How outlets are covering it

The Wall Street Journal and Fox News emphasize the volume of lawsuits and the lack of treatment for NAION. USA Today highlights the discrepancy between U.S. and international drug labels, noting that some countries have added NAION warnings. KBTX News 3 focuses on the permanent nature of the vision loss and the specific cases of patients who became legally blind. Novo Nordisk and Eli Lilly dispute the allegations, with Novo Nordisk calling the lawsuits meritless and pointing to company-funded research finding no increased risk. Eli Lilly maintains that current studies do not prove causation. The FDA is reviewing the evidence but has not concluded that semaglutide causes NAION or issued a safety warning. The European Medicines Agency, however, concluded there is sufficient evidence of a possible association to recommend adding NAION as a 'very rare' adverse reaction to semaglutide product information in Europe.

Why it matters

The potential link between GLP-1 drugs and NAION raises concerns about the safety of widely used weight-loss medications. If a causal link is established, it could lead to changes in drug labels, prescribing practices, and potential liability for manufacturers. The lack of treatment for NAION makes the risk particularly concerning for patients.

What to watch

The FDA will continue to review the evidence regarding a possible association between semaglutide and NAION. The lawsuits are expected to continue, with some claims consolidated into larger federal and state litigation. Manufacturers will likely continue to defend the safety of their drugs, while plaintiffs will argue that the companies failed to warn patients of the risk.